Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nandrolone Phenpropionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | SHBG | P04278 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nandrolone Phenpropionate SCHEMBL29396630 | 0.89 | MAPT (1.00) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| Nandrolone Phenpropionate SCHEMBL15285479 | 0.89 | MAPT (1.00) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| Nandrolone Phenpropionate SCHEMBL8443 | 0.89 | MAPT (1.00) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| Nandrolone Phenpropionate SCHEMBL29290732 | 0.86 | MAPT (0.93) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| Nandrolone Phenpropionate SCHEMBL6151232 | 0.85 | MAPT (0.92) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| Nandrolone Phenpropionate SCHEMBL1767545 | 0.82 | MAPT (0.86) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| Nandrolone Phenpropionate SCHEMBL28167686 | 0.81 | MAPT (0.82) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| SCHEMBL21067996 | 0.80 | MAPT (0.84) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| SCHEMBL23752494 | 0.78 | MAPT (0.78) | MAPTLMNAALDH1A1HIF1AMCL1 | |
| SCHEMBL17419472 | 0.78 | MAPT (0.78) | MAPTLMNAALDH1A1HIF1AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265710-A1 | HUMAN ADIPOSE DERIVED INSULIN MAKING MESENCHYMAL STEM CELLS FOR TREATING DIABETES MELLITUS | Smt. G R Doshi And Smt. K M Mehta Institute Of Kidney Diseases And Research Centre (IN) | 2010-12-29 | — | — | EP | claimed |
| WO-2009116087-A1 | HUMAN ADIPOSE DERIVED INSULIN MAKING MESENCHYMAL STEM CELLS FOR TREATING DIABETES MELLITUS | SMT. G R DOSHI AND SMT. K M MEHTA INSTITUTE OF KIDNEY DISEASES AND RESEARCH CENTRE (IN) | 2009-09-24 | — | — | WO | claimed |
| US-11090337-B2 | Preparation of photoreceptors for the treatment of retinal diseases | CELL CURE NEUROSCIENCES LTD (IL) | 2021-08-17 | — | — | US | disclosed |
| EP-3331995-A1 | PREPARATION OF PHOTORECEPTORS FOR THE TREATMENT OF RETINAL DISEASES | Cell Cure Neurosciences Ltd. (IL) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017021972-A1 | PREPARATION OF PHOTORECEPTORS FOR THE TREATMENT OF RETINAL DISEASES | CELL CURE NEUROSCIENCES LTD. (IL) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090337-B2 | Preparation of photoreceptors for the treatment of retinal diseases | ALDH1A2, PDE6C, PDE6B | AR 4789/4885MAPT 2779/4885LMNA 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.